
Lupin Limited has informed the Exchange regarding a press release dated May 26, 2025, titled "Lupin Announces Presentation of Phase 1 Data on LNP7457 (PRMT5 inhibitor) at theAmerican Society of Clinical Oncology - Annual Meeting 2025".
Filed with NSE ·

Lupin Limited has informed the Exchange regarding a press release dated May 26, 2025, titled "Lupin Announces Presentation of Phase 1 Data on LNP7457 (PRMT5 inhibitor) at theAmerican Society of Clinical Oncology - Annual Meeting 2025".
6ix hasn’t read this filing yet.
Follow Lupin into a list and get an email when it puts out news.
Follow Lupin